Anti-Anxiety
Drug Xanax Manufacturing Lab Found in Delhi
Ø
Illicit
laboratory operating under the guise of a computer shop unearthed in Ghazipur,
New Delhi; Officials dismantle complete manufacturing setup
·
Operation (15–16 November 2026): The
Directorate of Revenue Intelligence (DRI) busted a clandestine laboratory
manufacturing Alprazolam at Ghazipur, New Delhi, operating under the cover of a
computer shop.
·
Laboratory setup: The
premises contained a fully operational clandestine laboratory equipped with
reaction apparatus, water chiller, vacuum exhaust machine and other
manufacturing equipment.
·
Seizures:
o
148 kg of Alprazolam intermediate in
solid and liquid form.
o
Approximately 1,046 kg of raw materials and
chemicals.
o
188 litres of additional chemicals/liquids
used in the manufacturing process.
o
Laboratory equipment and associated materials.
·
Legal action: All seized materials and
equipment were seized under the NDPS Act, 1985, and the person operating
the laboratory was arrested.
·
Alprazolam: A benzodiazepine-class
psychotropic substance commonly marketed as Xanax and Alprax,
prescribed for anxiety and panic disorders, but prone to misuse, dependence and
diversion into illicit channels. Its unauthorised manufacture, possession, sale
and distribution are punishable under the NDPS Act.
·
Recent precedent: The
operation follows DRI's bust of a synthetic drug manufacturing laboratory in Jalaun district, Uttar Pradesh, on 29 October
2026, with assistance from UP ATS, resulting in seizure of approximately 1,100
kg of drugs and precursor chemicals, manufacturing equipment and the arrest
of two persons.
·
Significance: The successive operations
highlight DRI's intensified efforts to dismantle clandestine drug manufacturing
facilities and disrupt illicit supply chains involving psychotropic substances,
intermediates and precursor chemicals.
In
a significant crackdown on clandestine manufacturing of narcotic drugs and
psychotropic substances in India, the Directorate of Revenue Intelligence
(DRI), busted an illicit laboratory manufacturing Alprazolam at Ghazipur, New
Delhi, during 15–16 November 2026.
In
an intelligence led operation, DRI officers searched a premises
which was deceptively operating under the façade of a computer shop. The search
revealed a fully functional clandestine laboratory equipped with reaction
apparatus, a water chiller, a vacuum exhaust machine and other equipment used
in the manufacturing process.
The
operation resulted in the recovery of 148 kg Alprazolam intermediate in solid
and liquid form, along with approximately 1,046 kg raw materials and chemicals
and 188 litres additional chemicals/liquids used in the manufacturing process.
The laboratory equipment and associated materials were also seized under the
provisions of the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
The
person operating the clandestine laboratory was arrested under the provisions
of the NDPS Act, 1985.
Alprazolam
is a benzodiazepine-class psychotropic substance, commonly marketed under brand
names such as Xanax, Alprax etc. It is a prescription
medicine used primarily for the treatment of anxiety and panic disorders.
However, its misuse, dependence potential and diversion into illicit channels
pose significant public health concerns. Alprazolam is a notified psychotropic
substance under the NDPS Act, 1985, and its unauthorised manufacture,
possession, sale and distribution attract penal provisions of the Act.
This
operation follows DRI's recent busting of a major clandestine synthetic drug
manufacturing laboratory in Jalaun district, Uttar
Pradesh, on 29 October 2026, with operational assistance from UP ATS. The
operation had resulted in the seizure of approximately 1,100 kg of drugs and
precursor chemicals, along with manufacturing equipment, and the arrest of two
persons.
The
busting of the clandestine laboratory in Delhi within weeks of the Jalaun operation underscores DRI's intensified focus on
identifying and dismantling illicit drug manufacturing facilities, removing
substantial quantities of intermediate materials and precursor chemicals from
the illicit supply chain, and disrupting the networks sustaining such
operations.